Genomic and molecular characterisation of a KPC-producing Klebsiella pneumoniae clinical isolate resistant to meropenem-vaborbactam, imipenem-relebactam, and ceftazidime-avibactam. [PDF]
Wan Y +13 more
europepmc +2 more sources
Ignacy Tarski,1 Jakub Śmiechowicz,2 Wiesława Duszyńska2 1Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland; 2Department and Clinic of Anesthesiology and Intensive Therapy, Wroclaw Medical University, Wroclaw ...
Tarski I, Śmiechowicz J, Duszyńska W
doaj
Antimicrobial activity of aztreonam/avibactam and molecular characterization of Enterobacterales not susceptible to ceftazidime/avibactam and/or meropenem/vaborbactam from US medical centres (2016-2024). [PDF]
Sader HS +5 more
europepmc +1 more source
Assessing Clinical Effectiveness of Ceftolozane/Tazobactam, Ceftazidime/Avibactam, and Meropenem/Vaborbactam in Bacteremia: A Systematic Review and Meta-Analysis. [PDF]
Mohammad S, Albalas M, Al-Ahmad MM.
europepmc +1 more source
Successful Treatment with Imipenem/Cilastatin/ Relebactam of a Polymicrobial Bacteremia due to Meropenem/Vaborbactam-Resistant KPC-Kp and Enterococcus Faecalis. [PDF]
Marzi F +5 more
europepmc +1 more source
Complete genome sequences of KPC-producing <i>Klebsiella pneumoniae</i> isolates pre- and post-development of meropenem/vaborbactam resistance. [PDF]
Ozer EA +5 more
europepmc +1 more source
Carbapenem-Resistant Gram-Negative Bacteria: Mechanisms, Pathogen-Specific Strategies
Xiangquan Li,1,* Xing Tang,2,* Huafeng Ding,1,* Jiaqiong Li1,21Intensive Care Unit, Xuzhou Central Hospital, Southeast University, Xuzhou, Jiangsu, People’s Republic of China; 2Intensive Care Unit, The Xuzhou Clinical College ...
Li X, Tang X, Ding H, Li J
doaj
In vivo pharmacokinetic analysis of meropenem/vaborbactam during continuous venovenous haemodialysis
Wesley D Kufel +5 more
openaire +2 more sources
Targeting carbapenem-resistant and hypervirulent Klebsiella pneumoniae: in vitro evaluation of cefepime/zidebactam, aztreonam/avibactam, imipenem/relebactam, and meropenem/vaborbactam. [PDF]
Li Y, Li Y, Jia X, Mao H, Li D, Zhang J.
europepmc +1 more source
Effectiveness and safety of meropenem-vaborbactam versus ceftazidime-avibactam in multidrug-resistant Gram-negative infections: a systematic review and meta-analysis with trial sequential analysis. [PDF]
Mohammad S +4 more
europepmc +1 more source

